PBTC 039 - Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma

Description:

For complete information, please visit the study on clinicaltrials.gov

This study is being done in collaboration with Cincinnati Children's Hospital.

Medication Under Study:
Peginterferon alfa-2b

Full IRB Study Title:
PBTC-039: Phase II Study of Peginterferon alfa-2b (PEGIntron) for Pediatric Patients with Un-resectable or Recurrent Craniopharyngioma - Cincinnati

IRB Study ID:
141110

If you are interested in this study or have questions about your child's eligibility, please contact: Rebecca D. Considine Research Institute, 330-543-5012


Lead Principal Investigator:

Photo
Steven Kuerbitz, MD
Director, Divisional Research and Stem Cell Transplantation


Bookmark and Share

Developments Developments
Sign up for enewsletter
Get involved Get involved
Discover ways to support Akron Children's
    Contact Us

    330-543-5012

    E-mail

    find a location
    Find a location Type the first 3-5 letters of a specialty, service or location:
    Or, view: a map, a list of all locations, locations by city or locations near me.
    find a doctor
    Find a doctor Type the first 3-5 letters of the name, location or specialty:
    Or, view a list of all doctors by name, location and specialty.